New publication in the scientific journal BMC Neurology: Efficacy of the Cefaly device on refractory migraines
Cefaly Technology starts the year with a 30% growth
Cefaly Technology signs a contract with Bangladesh
Cefaly Technology signs a contract with South Africa
Launch of Cefaly 2 in Europe
Launch of Cefaly 2 in the USA
Migraine Medical Device, Cefaly, Shows Better Long-Term Patient Compliance than Migraine Medication
Cefaly Technology signs a record-breaking contract in China
December 2015, Cefaly Technology signs a record-breaking contract of € 6.5 million in China with the Angenieux Trading Shanghai Co Ltd.
The Belgian Brain Council announces the 2016 Cefaly Technology Award
Granting € 15,000, it will reward a specific research project in clinical and/or fundamental neuroscience which will contribute to increasing knowledge about the brain and its diseases or dysfunctions.
New study finds Cefaly has very high efficacy for migraine prevention
Results from a new clinical trial, published in The Journal of Headache and Pain, confirm the FDA-approved device has 81% efficacy among migraine sufferers.
>> read more
New Study Shows CEFALY Activity on Head and Neck Muscles in Chronic Migraine Patients
June 2015: New Study Shows CEFALY Activity on Head and Neck Muscles in Chronic Migraine Patients.
>> read more
Cefaly Technology signs an agreement protocol with the Hangzou Normal University
25th June 2015, Cefaly Technology and the Coma Science Group from the University of Liège sign an agreement protocol in Shangai with the Hangzou Normal University during the official state visit of King Philippe and Queen Mathilde to the People's Republic of China.
Cefaly Technology presents data from a new PET scan trial at the International Headache Society Congress in Valencia, Spain
May 14-17, The new study shows Cefaly returns metabolism activity to brain areas in migraine patients
Pierre Rigaux voted ‘Manager liégeois de l'année 2014’
As part of the ‘Citoyen de l’Année 2014’ action, organised by the Sud Presse Group in collaboration with the Loterie nationale, RTC and RTBF (Vivacité) in the region of Liège, Mr Pierre Rigaux, CEO of Cefaly Technology, was attributed the award of ‘Manager liégeois de l'année 2014’ during a gala event held on February 3 at the Forum in Liège.
10,000 U.S. Migraine patients who used FDA-Approved Cefaly device find relief
Early January 2015, Cefaly Technology is pleased to report that the Cefaly® sales have passed the 10,000 units mark. This symbolic milestone, illustrates that Cefaly® has indeed found a way to help migraineurs control, even eliminate, their migraines. The U.S. data of more than 10,000 patients shows more than a 94% success rate..."
Migraine Prevention Device CEFALY® Opens U.S. Office for Faster Delivery, Quicker Relief
On December, Cefaly® has opened its first U.S. office in Darien, Connecticut. The new space will serve as the exclusive distributor of Cefaly® in the United States. The devices will ship from a contracted warehouse in Pennsylvania.
Cefaly Techology voted ‘L’Entreprise Prometteuse de l’Année®’
On October 14th CEFALY Technology received the ‘L’Entreprise Prometteuse de l’Année®’ award. The award is granted by EY advisory company with the support of BNP Paribas and L’Echo, and honours a young company in full expansion.
"By choosing CEFALY Technology from a group of remarkable and promising nominees, the ‘L’Entreprise Prometteuse de l’Année 2014®’ jury is honoring a company that has developed a very innovative product with great international potential. The company has a mature and experienced management team that in the future perhaps will guide the company to the distinction of ‘L'Entreprise the l'Année®’. This indeed is the jury’s wish for the company", has concluded Pierre Rion, jury chairman.
Visit of Jean-Claude Marcourt, Vice-President of the Walloon Government
On April 23, Jean-Claude Marcourt, Vice-President of the Walloon Government and Minister in charge of the Economy, the SMEs, the Foreign Trade and the New Technologies, and Vice-President of the Wallonia-Brussels Federation and Minister in charge of Higher Education, came to the company's headquarter for a workshop on the development of the company's activities and on the significant growth of the exportation faced by the company.
Launch of export to the USA
April 1st is the real start of the commercialization of the Cefaly in the United States. The publication in March by the FDA of a press release about the market authorisation of the Cefaly in the US has been covered by all important US media including CNN, Fox News, … This national diffusion has boosted significantly the Cefaly sales in the US. About one thousand orders were placed since the FDA publication of the market authorization of the Cefaly.
The company received from the US Food and Drug Administration (FDA) on March 8, the authorization to market its medical device Cefaly in the United States. The Cefaly was already protected by a US patent covering not only its technology but also its method. This market authorization given by the FDA not only gives a recognition to the device quality and efficacy but also opens right away, and in a quasi–exclusive manner, the US market.
Participation to the economic princely mission to Saudi Arabia and the Sultanate of Oman
From 14 to 20 March 2014, Cefaly Technology took part to the economic princely mission organized in Saudi Arabia and in the Sultanate of Oman. This mission, chaired by HRH Princess Astrid representing King Philippe, allowed to prolong the first contacts taken during the Arab Health Exhibition organized in january 2014 in Dubaï and, amongst others, to set up a collaboration agreement with an important Saudi distribution company.
Participation to Arab Health
As each year since about 5 years, Cefaly Technology was present begin of this year in Dubaï and took part from 27 to 30 January to the Arab Health Exhibition, the Middle-East's largest professional fair dedicated to health. About 125 000 professional visitors, distributors and Neurology specialists originating mainly from the Middle-East have had a chance to test the efficacy of the Cefaly on the space reserved to the company within the Belgian Pavilion. In-depth contacts have been established with the perspective of future distribution partnerships for the Cefaly in Middle-East and particularly in Saudi Arabia and in Oman.